05 Nov 2019 SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases
04 Nov 2019 Compugen Announces FDA Clearance of IND Application for COM902
04 Nov 2019 Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
01 Nov 2019 Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
01 Nov 2019 Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
31 Oct 2019 Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
30 Oct 2019 CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
30 Oct 2019 FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
29 Oct 2019 Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
29 Oct 2019 Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
29 Oct 2019 Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
29 Oct 2019 Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
29 Oct 2019 European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
29 Oct 2019 MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
28 Oct 2019 Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer
28 Oct 2019 Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
28 Oct 2019 NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
28 Oct 2019 Y-mAbs Announces Positive Omburtamab Clinical Data
28 Oct 2019 Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
28 Oct 2019 Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference
28 Oct 2019 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
28 Oct 2019 Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar candidate FYB202
27 Oct 2019 Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
25 Oct 2019 MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
25 Oct 2019 Y-mAbs Announces Naxitamab Update

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up